The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
-
Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson, Arizona, United States, 85741
Norcal Endocrinology & Internal Medicine, San Ramon, California, United States, 94583
Southern California Clinical Research, Santa Ana, California, United States, 92701
Care Access - Thousand Oaks, Thousand Oaks, California, United States, 91360
Accel Research Sites - DeLand Clinical Research Unit, DeLand, Florida, United States, 32720
Innovation Medical Research Center - Fort Lauderdale, Fort Lauderdale, Florida, United States, 33316
Encore Medical Research, Hollywood, Florida, United States, 33024
West Orange Endocrinology P.A., Ocoee, Florida, United States, 34761
Care Access - Tampa, Tampa, Florida, United States, 33625
Care Access - Decatur, Decatur, Georgia, United States, 30030
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Eli Lilly and Company,
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company
2027-08